Asset / Drug

Lamotrigine

Drug and asset intelligence for Lamotrigine with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

RegulatoryJune 7, 2026

Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.

StrategyJune 6, 2026

Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.

No catalysts indexed for this entity yet.

Topline Data

Monitor the review progress and any subsequent approval announcements from the FDA regarding this application.

June 7, 2026 · N/A

Topline Data

Monitor for the launch timeline and market entry of Aurobindo's Lamotrigine product.

June 6, 2026 · N/A

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.